Zoom Logo

October New Practitioner Webinar - Shared screen with speaker view
Ian Pereira
12:29
Thank you for organizing this.
ACRO STAFF
14:55
Hi everyone, welcome! we've muted everyone for now but we'll open up for questions when Dr. Gomez wraps up the talk.
Ian Pereira
15:42
Much better!
Gregg Franklin
01:03:58
Can we get a .pdf of the talk?
John Han Chih Chang
01:04:04
Will the slides be available?
Soheila Azghadi
01:04:29
Thanks Dr. Gomez for the wonderful presentation!
Ian Pereira
01:05:41
Dear Dr. Gomez - you mentioned features from prior studies that may be used to guide definition of an "oligometstatic state" amenable to more aggressive treatment
Philip Blumenfeld
01:05:43
Thank you! This is a practical question: i have had difficulty making case to insurance companies to cover oligoprogessive lesions. any advice on making that argument
Ian Pereira
01:05:48
Do you have any guidelines that you use?
Ian Pereira
01:06:44
thanks you!
Michael Bernstein
01:07:32
Dear all,
Michael Bernstein
01:08:01
Sorry for the background technical difficulties. please send your questions to Dr. Gomez directly via chat and he can answer
Emma Dunne
01:08:40
Thank you for the great talk, have you noticed any particular barriers to recruitment to these trials?
Michael Bernstein
01:11:23
Hi Dr. Gomez, you alluded to timing of SAbR with systemic therapy. Do you anticipate an ideal sequence, perhaps importantly with increasing use of immunotherapy, concurrent, neoadjuvant, adjuvant? Thank you
Ian Pereira
01:13:41
Thank you Dr. Bernstein and Dr. Gomez!